AbbVie (ABBV) Depreciation & Amortization (CF) (2012 - 2026)

AbbVie (ABBV) has 15 years of Depreciation & Amortization (CF) data on file, last reported at $188.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $188.0 million, up 3.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $769.0 million (up 0.92% YoY), and the FY2025 annual result was $762.0 million, changed 0.26% from the prior year.
• Depreciation & Amortization (CF) eased to $188.0 million in Q1 2026 per ABBV's latest filing, from $203.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $206.0 million in Q4 2024 and troughed at $179.0 million in Q1 2023.
• A 5-year average of $190.8 million and a median of $190.0 million in 2023 frame the typical range for Depreciation & Amortization (CF).
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 13.29% in 2022 and fell as far as 18.83% in 2022.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $196.0 million in 2022, then dropped by 4.59% to $187.0 million in 2023, then gained by 10.16% to $206.0 million in 2024, then dropped by 1.46% to $203.0 million in 2025, then decreased by 7.39% to $188.0 million in 2026.
• Business Quant data shows ABBV's Depreciation & Amortization (CF) at $188.0 million in Q1 2026, $203.0 million in Q4 2025, and $192.0 million in Q3 2025.